Publications by authors named "K F Bartizal"
Article Synopsis
- Rezafungin, a long-acting echinocandin, is effective for treating candidemia and invasive candidiasis, showing non-inferiority to caspofungin in a Phase 3 study.
- The study included 93 patients on rezafungin and 94 on caspofungin, with similar baseline species distribution across groups and comparable cure rates and mortality outcomes.
- Efficacy was not affected by minimum inhibitory concentration values, and two patients with non-susceptible isolates had successful outcomes with rezafungin treatment.
Article Synopsis
- Previous attempts at creating safer antifungal treatments were based on an outdated model, focusing on how they damage fungal cell membranes.
- Researchers discovered that the key to the antifungal action of amphotericin B, a potent but kidney-damaging drug, lies in its ability to form sponge-like aggregates that extract crucial components from fungi.
- By modifying amphotericin B to selectively extract ergosterol without harming human kidneys, scientists developed a new polyene compound, AM-2-19, which shows promise as a safer and effective treatment against various fungal infections.
Background: Rezafungin is an investigational echinocandin under development for the treatment and prevention of invasive fungal infections, with a long half-life in humans (∼130 h) and potent in vitro activity against Aspergillus spp. Our objective was to further evaluate its activity against Aspergillus fumigatus isolates, including azole-resistant isolates and cryptic Aspergillus spp.
Methods: Clinical isolates of Aspergillus were used, including 15 WT and 31 azole-resistant A.
Background: While echinocandins demonstrate excellent efficacy against species in disseminated infections and demonstrate potent minimal inhibitory concentration (MIC) values under standard susceptibility testing conditions, investigation under conditions relevant to the vaginal environment was needed. We assessed the antifungal activity and time-kill kinetics of the novel echinocandin rezafungin (formerly CD101) under such conditions, against species relevant to vulvovaginal candidiasis (VVC).
Methods: Susceptibility testing of fluconazole-susceptible and fluconazole-resistant , , , , and was performed in RPMI at pH 7.
Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters.
Antimicrob Agents Chemother
November 2017
CD101 is a novel echinocandin with concentration-dependent fungicidal activity and a long half-life (∼133 h in humans, ∼70 to 80 h in mice). Given these characteristics, it is likely that the shape of the CD101 exposure (i.e.
View Article and Find Full Text PDF